At minimum, two to three sessions per week of weight-bearing or resistance exercise is what most sports medicine and orthopedic specialists would recommend for a patient on GLP-1 therapy
for the VERTIS CV Investigators
This means Tirzepatide is available as a prescription pharmaceutical with established pharmacovigilance infrastructure, manufacturing standards, and post-market safety monitoring programs
The ~21-day half-life means patients require only 12 injections per year compared to 52 with weekly therapies
gastric ulcers, duodenal ulcers, and mucosal erosion where direct local peptide delivery to the damaged tissue is the therapeutic goal Inflammatory bowel conditions: Crohn's disease and ulcerative colitis support, where VEGF-mediated mucosal angiogenesis and anti-inflammatory effects have been investigated Leaky gut and intestinal hyperpermeability: tight junction restoration and mucosal integrity support in patients with compromised gut barrier function Gastroparesis: pro-motility effects via vagal cholinergic pathways investigated in preclinical models of delayed gastric emptying
What are the Potential Side Effects